Abstract: Disclosed herein are systems, methods, and computer-readable storage devices for manufacturing patient-specific bolus for use in targeted radiotherapy treatment. Based on dose calculations without a bolus and based on three-dimensional scan data of a patient, the example system generates a model of a bolus for targeting radiotherapy treatment to a planning target volume or target region within the patient. The system can perform several iterations to generate a resulting model for the bolus. Then, the system can generate instructions for controlling a three-dimensional printer to generate the bolus that conforms to the patient's skin surface while also specifically targeting the planning target volume for the radiotherapy treatment. In this way, the amount of radiotherapy treatment administered to other tissue is reduced, while the costs, time, and human involvement in creating the bolus are significantly reduced.

Abstract: A compound having a chemical formula according to Formula (I) is disclosed where one of Z1, Z2 and Z3 is and one of the Z1, Z2, and Z3 that is bonded to a carbon atom that is adjacent to the carbon atom bonded to is P(AR1)(A?R2). Metal-based catalyst and pre-catalysts, such as nickel-based catalysts and precatalysts, where the metal is complexed to the compound are also disclosed. Methods of forming C(sp2)-N bonds are also disclosed.

Abstract: Methods are provided for the treatment of Parkinson's disease (PD) in patients bearing mutations in the LRRK2 gene. A therapeutically effective amount of piperazine derivative compounds are employed to inhibit the biological activity of ArfGAP1, inhibition that counteracts the deleterious effects of mutations in, or increased expression of, the LRRK2 protein.

Abstract: Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are compounds which contain bioisosteric replacements of the urea group of JTE-013 and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.

Abstract: A high frequency ultrasound analog beamformer comprises a linear array of surface acoustic wave (SAW) devices formed on a single crystal piezoelectric substrate, such as a PMN-PT single crystal piezoelectric substrate. Each SAW device comprises ultrasound input and output electrode structures separated by a variable delay structure. The beamformer further comprises a delay controller operably connected to each variable delay structure to control the delay of each SAW device to dynamically focus signals received at each input electrode.

Abstract: The present invention provides a method for removing a tattoo in a region of skin the method comprises administering to a least a portion of the tattoo a composition comprising an effective amount of a bisphosphonate and at least one pharmaceutically acceptable excipient to at least cause fading of the tattoo in said region.

Abstract: To address limitations of conventional transducers, a phased array transducer is provided with a form factor suitable o for packaging into, e.g., an endoscope. A method of manufacture of small packaging transducers is also provided, whereby the overall package size is reduced by electrically connecting signal wires to array electrodes at an angle approximately normal to the array surface, thus largely eliminating the bend radius requirements of conventional printed circuit boards or flex circuits.

Abstract: The present invention provides a method for removing a tattoo in a region of skin the method comprises administering to a least a portion of the tattoo, and a composition comprising an effective amount of a bisphosphonate and at least one pharmaceutically acceptable excipient to at least cause fading of the tattoo in said region.

Abstract: Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the administration of a therapeutically effective amount of a Sphingosine-1-phosphate receptor type 2 (S1PR2) inhibitor.

Abstract: A method for quantifying, during pacemapping, a comparison of a BSPM of interest to a pace site BSPM. The method may include receiving at a computing device a plurality of ECG signals from an acquisition system. The pace site BSPM may be calculated using the plurality of ECG signals. The BSPM of interest may be compared to the pace site BSPM, by: retrieving the BSPM of interest from memory accessible by the computing device; and, calculating one or more comparison metrics for the BSPM of interest as compared to the pace site BSPM. An indication of similarity between the BSPM of interest and the pace site BSPM based on the comparison metric calculated may be displayed on a user interface in communication with the computing device.

Abstract: Among other things, in general, an acousto-mechanical transducer for the interconversion of electricity and acoustic waves is described. Methods are also described for the construction of such transducers.

Abstract: A method for quantifying, during pacemapping, a comparison of a BSPM of interest to a pace site BSPM. The method may include receiving at a computing device a plurality of ECG signals from an acquisition system. The pace site BSPM may be calculated using the plurality of ECG signals. The BSPM of interest may be compared to the pace site BSPM, by: retrieving the BSPM of interest from memory accessible by the computing device and, calculating one or more comparison metrics for the BSPM of interest as compared to the pace site BSPM. An indication of similarity between the BSPM of interest and the pace site BSPM based on the comparison metric calculated may be displayed on a user interface in communication with the computing device.

Abstract: A method for quantifying, during pacemapping, a comparison of a BSPM of interest to a pace site BSPM. The method may include receiving at a computing device a plurality of ECG signals from an acquisition system. The pace site BSPM may be calculated using the plurality of ECG signals. The BSPM of interest may be compared to the pace site BSPM, by: retrieving the BSPM of interest from memory accessible by the computing device and, calculating one or more comparison metrics for the BSPM of interest as compared to the pace site BSPM. An indication of similarity between the BSPM of interest and the pace site BSPM based on the comparison metric calculated may be displayed on a user interface in communication with the computing device.

Abstract: A method for quantifying, during pacemapping, a comparison of a BSPM of interest to a pace site BSPM. The method may include receiving at a computing device a plurality of ECG signals from an acquisition system. The pace site BSPM may be calculated using the plurality of ECG signals. The BSPM of interest may be compared to the pace site BSPM, by: retrieving the BSPM of interest from memory accessible by the computing device; and, calculating one or more comparison metrics for the BSPM of interest as compared to the pace site BSPM. An indication of similarity between the BSPM of interest and the pace site BSPM based on the comparison metric calculated may be displayed on a user interface in communication with the computing device.

Abstract: High-frequency ultrasound imaging can be performed with greater quality and suppressed grating lobes by using methods and systems for effectively reducing the temporal length of transmit grating lobe signals in received ultrasound echoes. Systems and methods are provided for improved high-frequency ultrasound imaging. In various aspects, the method of shortening the time domain of grating lobe signals comprises splitting an array of N transmit elements into K sub-apertures. In further aspects, the grating lobes are suppressed by performing signal processing of the shortened grating lobe signals. In certain aspects, the signal processing method comprises weighting the samples by a calculated phase coherence factor.

Abstract: Among other things, piezoelectric materials and methods of their manufacture are described; particularly methods of forming regions of varying crystal structure within a relaxor piezoelectric substrate. Such methods may including heating the piezoelectric substrate above the transition temperature and below the Curie temperature such that a first phase transition occurs to a first crystal structure; rapidly cooling the piezoelectric substrate below the transition temperature at a cooling rate that is sufficiently high for the first crystal structure to persist; and applying an electric field through one or more selected regions of the piezoelectric substrate, such that within the one or more selected regions, a second phase transition occurs and results in a second crystal structure.

Abstract: Amblyopia is a prevalent form of visual impairment that generally arises during infancy and early childhood when inputs to the visual cortex form the two eyes are poorly balanced. Disclosed herein are methods involving retinal inactivation of at least one retina to treat visual impairment in the form of amblyopia or other conditions.

Abstract: Disclosed herein are compositions and methods for making germanium-based glass polyalkenoate cements. Also disclosed are methods for their use as bone cements for bone augmentation procedures.

Abstract: Described herein are phenolic compositions derived from apple skins. In particular, described herein are flavonoid-rich fractions derived from apple skin extract. The compositions are useful in the prevention and treatment of conditions associated with oxidative stress and/or inflammation, including certain neurodegenerative diseases. Methods of producing the compositions are also described.

Abstract: Disclosed herein are compositions and methods for making germanium-based glass polyalkenoate cements. Also disclosed are methods for their use as bone cements for bone augmentation procedures.